1 Recommendations

1.1

This recommendation no longer stands.

1.5

This recommendation no longer stands.

1.6

This recommendation no longer stands.

1.7

It is recommended that a glycoprotein (GP) IIb/IIIa inhibitor is considered as an adjunct to percutaneous coronary intervention (PCI) for all patients with diabetes undergoing elective PCI, and for those patients undergoing complex procedures (for example, multi-vessel PCI, insertion of multiple stents, vein graft PCI or PCI for bifurcation lesions); currently only abciximab is licensed as an adjunct to PCI. In procedurally uncomplicated, elective PCI, where the risk of adverse sequelae is low, use of a GP IIb/IIIa inhibitor is not recommended unless unexpected immediate complications occur.

1.8

GP IIb/IIIa inhibitors are not currently licensed in the UK for use as an adjunct to thrombolytic therapy in ST-segment-elevation myocardial infarction (STEMI).